INTRODUCTION
The natural history of chronic myeloid leukemia (CML) has been irrevocably changed since the advent of tyrosine kinase inhibitors (TKIs). Imatinib, the first TKI to be successfully used in CML, became standard frontline therapy for patients with CML in 2001. Greater than 80% of patients with CML who are treated with imatinib as initial therapy are reported to achieve a complete cytogenetic response (CCyR) and approximately 70% achieve a major molecular response (MMR) by 5 years of therapy. 1 The use of TKIs as initial therapy has resulted in an improvement in survival, 2 such that survival rates currently mimic those of the general population 3, 4 and have resulted in an increase in the prevalence of the disease. 5 With prolonged survival, questions arise regarding the effects of TKI treatment on prior medical conditions and the effect of such conditions on the management and outcome of patients with CML. In some instances, patients with CML may have a preexisting diagnosis of another cancer, making CML the "second cancer." Recent population studies have suggested that there is an increased prevalence of other malignancies before the diagnosis of CML compared with the incidence in the general population. 6 To the best of our knowledge, the impact that a diagnosis of CML and treatment with TKIs may have on the prior cancer and the impact of the prior malignancy on the outcome of patients with CML receiving treatment with TKIs have not been described to date. Several hypothetical scenarios could be envisioned for patients with prior malignancies who develop CML. One is reactivation of the prior malignancy because of the therapy received for CML. The TKIs may have immunomodulatory effects as suggested by the in vitro inhibition of T-cell proliferation and activation by imatinib, nilotinib, and dasatinib. [7] [8] [9] Some TKIs such as dasatinib also inhibit SRC kinases, which are key regulators of immune responses. 8, [10] [11] [12] [13] An immunosuppressive effect of TKIs could potentially lead to reactivation of a prior malignancy. Another possible scenario is that having a prior malignancy adversely affects the prognosis of patients with CML or their ability to tolerate TKIs. For example, patients with secondary acute myeloid leukemia (AML) have inferior outcomes regardless of age or cytogenetics. 14 Similarly, a history of prior malignancies or the treatment of them could alter the clinical features or the clinical course of patients with CML.
The purpose of the current study was to investigate the frequency, characteristics, and outcome among patients with CML who were treated with TKIs and who had a history of prior malignancies.
MATERIALS AND METHODS
We analyzed the records of all patients with Philadelphia chromosome-positive CML in chronic phase who were treated with a TKI as their initial therapy in clinical trials conducted at The University of Texas MD Anderson Cancer Center from July 2000 to January 2014. The criteria for chronic-phase CML was as previously described. 15 These studies were approved by the Institutional Review Board, and all patients provided written approved informed consent in accordance with the Declaration of Helsinki.
Evaluation of Patients
All patients underwent a history and physical examination, complete blood counts, and blood chemistry panel before the initiation of therapy and at least once every month for the first 3 months, followed by every 3 months until 12 months from the initiation of therapy and then every 6 months thereafter. Cytogenetic response was assessed by G banding in the bone marrow with 20 metaphases counted, and MR was assessed by real-time polymerase chain reaction and expressed as the BCR-ABL/ABL ratio on the international scale. Both cytogenetic and MR assessments were performed at baseline, every 3 months for the first 12 months, and then every 6 months. Definitions of cytogenetic responses and MRs were standard. 15 The records of all patients were reviewed for a history of any malignancy diagnosed before the diagnosis of CML. All available clinical information related to the prior malignancy was collected, including the original diagnosis, stage of disease, treatment, response to therapy (if any), status of the prior malignancy at the time of CML diagnosis, and any change in the status of the prior malignancy after the initiation of therapy for CML.
Statistical Analysis
Summary statistics were used to describe the study population by groups. Overall survival (OS) was calculated as the number of months from the initiation of treatment to death or last follow-up date. Patients who were alive at the time of last follow-up were censored on that date. Eventfree-survival (EFS) was determined from the initiation of therapy with a TKI to loss of complete hematologic response, loss of major cytogenetic response (MCyR), transformation during treatment with the initial TKI, or death during therapy with the first TKI. Failure-free survival (FFS) was determined from the initiation of therapy with a TKI to the occurrence of an event (as defined above for EFS), loss of CCyR, development of intolerance, or discontinuation of TKI therapy for any reason. Transformation-free survival (TFS) was determined from the initiation of therapy with a TKI to transformation to accelerated phase or blast phase or death during therapy with the original TKI. The Pearson chi-square test (or the Fisher exact test) and the t test (or Wilcoxon rank sum test) were used to determine differences between the groups. The Kaplan-Meier product limit method was used to estimate the median OS, EFS, TFS, and FFS, respectively. Univariate Cox proportional hazards regression models were used to identify any association with each of the variables and OS, EFS, TFS, and FFS, respectively. Univariate and multivariate generalized linear models were used to model the relationship between response and demographic/clinical characteristics. Statistical analysis was performed using STATA/SE statistical software (version 14.1; StataCorp LP, College Station, TX).
RESULTS
During the study period, a total of 630 consecutive patients with CML in chronic phase were treated with a TKI as initial therapy. Of these, 626 patients had a documented prior malignancy and therefore constituted the basis for the current study. Among them, 73 patients (12%) were treated with imatinib at a starting dose of 400 mg/day, 204 patients (33%) were treated with imatinib at a starting dose of 800 mg/day, 150 patients (24%) were treated with
Original Article dasatinib at a dose of 100 mg/day, 148 patients (24%) were treated with nilotinib at a dose of 400 mg twice daily, and 51 patients (8%) were treated with ponatinib at a dose of 30 mg/day (n58) or 45 mg/day (n543). Among these 626 patients, 62 (10%) had a history of 72 malignancies before their diagnosis of CML. The patients were subdivided into 3 groups for the sake of this analysis: 1) patients without a cancer diagnosis before their diagnosis of CML (nPM); 2) patients who had a nonmelanoma skin cancer (nMSC); and 3) patients with a prior malignancy, not a nMSC (PM). The clinical characteristics of these patients are shown in Table 1 . Patients with prior malignancies, in both the nMSC and PM groups, were older than patients in the nPM group. There were no other clinically significant differences observed between the groups.
The most common prior malignancy was nMSC, with 20 cases reported in 18 patients, representing 28% of all prior cancers. Three patients had a recurrence of their nMSC and all were treated with surgery. Of the 20 cases of nMSC, 2 patients had 2 cases of nMSC and 1 patient had both nMSC and breast cancer. The patient with both breast cancer and nMSC was included within the PM group for the current analysis.
Forty-five patients with a prior malignancy were found to have had 52 instances of a malignancy that was not an nMSC. Three patients in the PM group had 2 different PMs (thyroid cancer and Hodgkin lymphoma, transitional bladder cancer and clear cell kidney cancer, and colon cancer and prostate cancer, respectively). Two patients had 3 PMs other than nMSC (renal cell cancer, One patient with nMSC was treated with radiotherapy. All other patients with nMSC were treated with simple or wide excision and were considered to be cured. Of the 52 remaining patients with malignancies, 24 (46%) were treated with chemotherapy, 20 (38%) had received radiotherapy, and 44 (85%) underwent surgery. Combined therapy was common, including 10 patients treated with surgery, chemotherapy, and radiotherapy; 6 patients treated with surgery and radiotherapy; 9 patients treated with surgery and chemotherapy; and 1 patient treated with chemotherapy and radiotherapy (see Supporting Information Table 1 ).
Status of Prior Malignancy at the Time of CML Diagnosis
Of the 45 patients in the PM group, 42 (93%) were found to have no active disease and were receiving no treatment for cancer at the time of their CML diagnosis. Two patients (4%) were still receiving treatment for their prior malignancy at the time of their diagnosis with CML. Both were receiving tamoxifen for breast cancer and had no evidence of disease. One patient (2%) had active disease at the time of the CML diagnosis (defined as diagnosis or documented treatment of a prior cancer within 6 months before or after the diagnosis of CML). This patient had undergone surgery for an early-stage melanoma 6 months before the diagnosis of CML was made and was being followed with observation only at the time of the CML diagnosis (see Supporting Information Table 1 ).
Outcome of Prior Malignancy After Diagnosis of CML
After treatment of CML was initiated, 41 of 45 patients (91%) in the PM group remained free of disease recurrence or progression of their non-CML malignancy. This included 1 patient with active stable melanoma noted on imaging, who had not been treated within 23 months before the diagnosis of CML; all other patients had no evidence of disease recurrence. Four patients had recurrence of their prior malignancy. One patient with recurrent melanoma diagnosed 13 months after the original diagnosis of melanoma and 6 months after initiating treatment with imatinib at a dose of 800 mg/day was treated with chemotherapy for recurrent melanoma. One patient developed recurrence of breast cancer that was treated with chemotherapy and radiotherapy and was diagnosed 151 months after the initial diagnosis of breast cancer and 40 months after initiating treatment with imatinib at a dose of 800 mg/day. One patient with recurrence of mucosaassociated lymphoid tissue lymphoma 113 months after their initial diagnosis and 11 months after initiating therapy with nilotinib was treated with radiotherapy. Finally, 1 patient with recurrent prostate cancer 49 months after the initial diagnosis and 25 months after initiating dasatinib was treated with radiotherapy (see Supporting Information Table 2 ). Three of these 4 patients continued treatment for CML with a TKI while being treated for recurrence of the prior malignancy. The one patient who did not continue therapy had his dose of imatinib (800 mg/day) withheld while he was being treated for metastatic malignant melanoma at an outside institution and died of unknown causes before being able to reinitiate therapy with a TKI. Twelve of the 45 patients in the PM group (27%) had died at the time of last follow-up. All died while being treated with a TKI. Two deaths were considered related to the PM (breast and melanoma, respectively) and there were no CML-related deaths reported.
CML Outcome
The median follow-up for all 626 patients included in the current analysis was 84 months (range, 0-180 months) from the initiation of therapy with the TKI. Among them, 563 patients (90%) achieved a CCyR, 529 patients (85%) achieved an MMR, and 425 patients (68%) achieved an MR with 4.5-log reduction (MR4.5). After 3 months of TKI therapy, 538 patients (86%) had achieved an MCyR. Overall, the 5-year EFS rate was 85% (95% confidence interval [95% CI], 81-87%), the 5-year FFS rate was 68% (95% CI, 64-72%), the 5-year TFS rate was 92% (95% CI, 89-94%), and the 5-year OS rate was 92%, (95% CI, 89-94%).
The 564 patients with no prior malignancies had a median follow-up of 86 months (range, 0-180 months) from the initiation of TKI therapy. Among them, 505 patients (90%) achieved a CCyR, 475 (84%) achieved an MMR, and 381 (68%) achieved an MR4.5. After 3 months of therapy with TKIs, 482 patients (85%) had achieved an MCyR. For this group of patients, the 5-year EFS rate was 84% (95% CI, 81-88%), the 5-year FFS rate was 68% (95% CI, 64-72%), the 5-year TFS rate was 93% (95% CI, 90-95%), and the 5-year OS rate was 93% (95% CI, 90-95%).
The 45 patients with prior malignancies had a median follow-up of 76 months (range, 12-172 months) from the initiation of TKI therapy. Among them, 43 patients (96%) achieved a CCyR, 41 patients (91%) achieved an MMR, and 36 patients (80%) achieved an MR4.5. After 3 months of therapy with TKIs, 41 patients (91%) had achieved an MCyR. For this cohort of patients, the 5-year EFS rate was 85% (95% CI, 66-94%), the 5-year FFS rate was 63% (95% CI, 46-76%), the 5-year TFS rate was 89% (95% CI, 69-96%), and the 5-year OS rate was 79% (95% CI, 63-89%).
The nMSC group of 17 patients had a median follow-up of 68 months (range, 9-157 months) from the initiation of therapy with TKIs. In this cohort, 15 patients (88%) achieved a CCyR, 13 patients (76%) achieved an MMR, and 8 patients (47%) achieved an MR4.5. After 3 months of therapy with TKIs, 15 patients (88%) had achieved an MCyR. In the nMSC group, the 5-year EFS rate was 86% (95% CI, 33-98%), the 5-year FFS rate was 70% (95% CI, 32-90%), the 5-year TFS rate was 86% (95% CI, 33-98%), and the 5-year OS rate was 100%.
Response rates were found to be similar across all cohorts. In addition, the long-term CML outcomes (EFS, FFS, and TFS) were noted to be equivalent between the 3 groups (Figs. 1A-1C) . However, there was a statistically significant difference in OS noted between the groups (Fig. 1D) . In the PM group, 12 patients (27%) had died at the time of last follow-up (median age at the time of death, 72 years [range, 52-91 years]). In contrast, in the nPM group, 65 patients (12%) had died (median age at the time of death, 63 years [range, 23-92 years]), and in the nMSC group, only 1 patient (6%) had died at the time of last follow-up (aged 80 years) (hazard ratio [HR], 2.40, 95% CI, 1.29-4.44) (see Supporting Information Table 3 ).
Univariate/Multivariate Analysis
We performed a generalized linear model analysis to evaluate the features associated with achieving an MR4.5. In a univariate analysis, the variables that were found to negatively predict achieving an MR4.5 were a platelet count Table 4) .
We then performed a multivariate Cox proportional hazards analysis to investigate features associated with survival. In a univariate analysis for OS, age, Sokal score, serum albumin <3.4 g/dL, blood urea nitrogen >20 mg/ dL, and a creatinine level >1.3 mg/dL were found to be associated with outcome. In multivariate analysis, only older age (HR, 1.05; 95% CI, 1.03-1.07 [P<.001]) and a creatinine level >1.3 mg/dL (HR, 3.09; 95% CI, 1.45-6.57 [P 5 .003]) were found to be independently associated with inferior survival probability. It is important to note that a history of prior malignancy was not found to be independently associated with OS probability (Table 2) .
Competing Risk Regression Analysis
We then performed a competing risk regression analysis to investigate whether the risk of death due to CML or another cause of death not related to CML was different when given variables were no longer competing for relevance. Age was not found to be statistically significant with regard to cause of death between CML deaths and deaths from other causes (HR, 1.02; 95% CI, 0.97-1.06 [P 5 .526]). Risk of death from non-CML causes was statistically significantly increased compared with the incidence of death from CML in the PM group (HR, 7.19e-08; 95% CI, 3.46e-08-1.49e-07 [P<.001]). The risk of death from CML versus other causes was statistically significantly increased when baseline bone marrow blasts were >10% (HR, 30.74; 95% CI, 6.88-137.37 [P<.001]) (see Supporting Information Table 5 ). In an analysis of the cumulative incidence of death, there were no CML-related deaths noted in the PM group and there was only 1 event reported the nMSC group, thereby preventing a comparison with this group. In the nPM group, the 5-year cumulative incidence of non-CML-specific death was 3.67% (95% CI, 2.21%-5.70%). In the PM group, the 5-year cumulative incidence of non-CML-specific death was 16.50% (95% CI, 6.61%-30.25%) (Fig. 2) .
DISCUSSION
With a better understanding of cancer biology and everimproving cancer therapies, the outcome for patients with various cancers has improved significantly in recent years. The death rate for all cancers in 1991 was 215.22 per 100,000 population, and declined to 175.86 per 100,000 population in 2008. 16 The annual percent change during this period ranged from -0.46 to -1.61. A natural consequence of the prolonged survival of patients with cancer is the possibility of their developing a second cancer. Second cancers may develop as a consequence of exposure to agents used for the treatment of the primary cancer. Exposure to some therapeutic modalities such as alkylating agents and radiotherapy may result in a significant increase in the risk of developing second cancers. 17 However, in many cases, no common etiologic link can be identified and a second cancer may occur as a result of prolonged survival with persistence of a constant annual risk of the development of seemingly unrelated malignancies. In the latter scenario, the incidence of a second cancer would be expected to be similar to that observed in the general population. We have previously reported on the occurrence of second cancers among patients with CML who were treated with a TKI. The incidence we reported was somewhat lower than expected in the general population, suggesting that TKIs do not increase the risk of second malignancies. 18 However, Scandinavian registry studies have reported different findings, suggesting an increased risk of secondary malignancies among patients with CML who are treated with TKIs. 19, 20 To the best of our knowledge, the current study is the first analysis of the outcome of prior malignancies among a large group of patients with CML who had such a prior history, as well as the outcome of CML among these patients. Patients with prior malignancies were older than their counterparts with no prior malignancies. Aside from this, there were no clinically significant differences noted with regard to the characteristics of patients with or without prior malignancies.
Considering the various types of cancers diagnosed among these patients, and the retrospective nature of the current analysis, we could not identify an obvious link between the prior malignancies and CML, whether related to a common genetic predisposition, from exposure to common predisposing environmental or other factors, or resulting from exposure to chemotherapy or radiotherapy used to manage the first malignancy. It is interesting to note that a registry report from the Swedish CML registry reported an increased prevalence of prior cancers among patients with CML compared with what is observed in the general population, with an OR of 1.47 (95% CI, 1.20-1.82). The investigators commented that this link suggests a possible hereditary or acquired predisposition toward cancer. 6 In our series, there were 52 incidences of cancer that were not nonmelanoma skin cancer noted before treatment of CML, and these most often were breast cancer, melanoma, other hematologic malignancies, prostate cancer, and colorectal cancer. There is some parallel in this, with the Swedish registry study noting a significantly increased incidence of breast cancer, gastrointestinal cancer, malignant melanoma, urinary tract cancers, and endocrine cancer. 6 In the current study, no difference in response to CML therapy was noted among patients with a prior malignancy compared with patients without such malignancies. The wide variability in tumor types (and likely stage of disease at the time of diagnosis, although this information was frequently inaccessible) preclude expectations of outcome for these patients. By definition, they all were survivors of their prior cancer at least long enough to develop CML. Only 4 of 45 patients experienced a recurrence of their prior cancer. Thus, it appears that the majority of these patients had been cured of their prior malignancy. With the excellent outcome achieved with the use of TKI therapy for their CML, the majority of these patients appear to have survived 2 (and in a few instances more) separate cancers.
The response to therapy observed with the use of TKIs for patients with prior malignancies was excellent, and similar to that observed among patients with no prior malignancies. Greater than 90% of patients achieved a CCyR and greater than two-thirds of patients achieved an MMR. This resulted in an excellent OS rate, with no cases of transformation to accelerated or blast phases reported. There was a trend toward a lower MR4.5 among patients with nMSC; this trend is of unknown significance and may represent only a statistical artifact.
Although AML is most frequently cited as a secondary malignancy, there are intermittent reports of CML as a second malignancy. A recently published report by Adra et al described 3 cases of CML after treatment of germ cell tumors. All 3 patients received alkylating chemotherapeutic agents and, of the 3 patients, 1 died of their germ cell tumor whereas the other 2 patients achieved at least some response to TKIs. 21 To the best of our knowledge, case series and reports are all that are described in the literature in any detail. 22 Patients with such secondary AML usually have a very poor prognosis, with low rates of response and cure, even after stem cell transplantation. 23 Their prognosis is inferior, even for patients with core-binding factor leukemias. 24 In contrast, according to the results of the current analysis, patients with CML have a similarly favorable outcome regardless of whether they have received therapy for a prior malignancy or never had a prior malignancy.
The results of the current study suggest that although outcomes for patients with CML are excellent, patients with CML as a second malignancy have a shorter survival. The results of multivariate analysis suggest that age and renal function (creatinine level) are the best predictors of OS, whereas a history of prior malignancy is not independently associated with survival. However, it is interesting to note that a competing risk analysis of the groups demonstrated that the PM and the nPM groups were more likely to die of causes other than CML (Fig. 2) .
The results of the current study indicate that survivors of prior malignancies who develop CML as a second (or later) malignancy may have a similarly excellent outcome with TKI therapy as patients for whom CML is their first malignancy. In fact, these data stress the importance of the control of other comorbid conditions after the diagnosis and treatment of CML. Therefore, these patients should be offered treatment with TKIs with the objective of the best possible outcome leading to survivorship from a second malignancy.
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